SCHEMBL2590837

SCHEMBL2590837

CCC(CC)(NCC(=O)O)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.36
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
THRB P10828 1/20 0.35
KMT2A Q03164 1/20 0.35
FPR2 P25090 1/20 0.35
CTH P32929 1/20 0.34
EGLN1 Q9GZT9 2/20 0.34
CYP2D6 P10635 2/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
PTGS2 P35354 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25995 0.79 ALDH1A1 (0.41) FFAR3ALDH1A1MEN1CYP1A2THRB
SCHEMBL11186495 0.79 GAA (0.46) ALDH1A1CYP1A2EGLN1TSHRSMN1; SMN2
SCHEMBL27917021 0.78 EGLN1 (0.34) FFAR3ALDH1A1FPR2CTHEGLN1
SCHEMBL27640176 0.75
SCHEMBL58233 0.74 ARG1 (0.36) FFAR3ALDH1A1MEN1CYP1A2THRB
SCHEMBL14420949 0.74 FFAR3 (0.40) FFAR3ALDH1A1MEN1CYP1A2THRB
SCHEMBL983535 0.73 FFAR3 (0.35) FFAR3ALDH1A1MEN1CYP1A2THRB
SCHEMBL624753 0.72 EGLN1 (0.40) FFAR3ALDH1A1MEN1CYP1A2THRB
Hydrochloric Acid SCHEMBL3607012 0.72 ARG1 (0.35) FFAR3ALDH1A1MEN1CYP1A2THRB
SCHEMBL17371358 0.72 ALDH1A1 (0.32) FFAR3ALDH1A1MEN1CYP1A2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112080560-B Use of CD177 for the preparation of a product for diagnosing biliary tract occlusion 广州市妇女儿童医疗中心(广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心) 2024-01-26 CN disclosed
CN-117288962-A Application of reagent for detecting marker combination in preparation of biliary tract locking diagnosis product 广州市妇女儿童医疗中心 2023-12-26 CN disclosed
EP-2729664-B1 SAMPLING PROCEDURE FOR POLYMER-BASED SOLUTIONS USED IN UNDERGROUND FORMATIONS SNF GROUP (FR) 2023-08-02 EP disclosed
WO-2022045240-A1 SEALING AGENT FOR LIQUID CRYSTAL DISPLAY ELEMENT, VERTICAL CONDUCTION MATERIAL, AND LIQUID CRYSTAL DISPLAY ELEMENT 積水化学工業株式会社 2022-03-03 WO disclosed
US-10364262-B2 Method for the synthesis of N-phosphonomethyliminodiacetic acid MONSANTO TECHNOLOGY LLC (US) 2019-07-30 US disclosed
CN-104854117-B Process for the synthesis of N-phosphonomethyliminodiacetic acid 孟山都技术有限责任公司 2018-12-25 CN disclosed
CN-103649462-B The sampling method of polymer-based solution for subterranean strata S.P.C.M.股份公司 2018-08-07 CN disclosed
US-9714889-B2 Sampling procedure for polymer-based solutions used in underground formations S.P.C.M. SA (FR) 2017-07-25 US disclosed
EP-2563122-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2016-06-08 EP disclosed
CN-102428157-B The water-soluble polymers of single mixed thing and the new formulation of stabilization additives that chemistry improves oil recovery injection fluid is can be used for for injecting S.P.C.M. S.A. (FR) 2015-09-09 CN disclosed
WO-2014012986-A1 METHOD FOR THE SYNTHESIS OF N-PHOSPHONOMETHYLIMINODIACETIC ACID STRAITMARK HOLDING AG (CH) 2014-01-23 WO disclosed
EP-2563122-A1 CHEMICAL COMPOUNDS Glaxosmithkline LLC (US) 2013-03-06 EP disclosed
US-20130029938-A1 Chemical Compounds GLAXOSMITHKLINE LLC (US) 2013-01-31 US disclosed
WO-2013004650-A1 SAMPLING PROCEDURE FOR POLYMER-BASED SOLUTIONS USED IN UNDERGROUND FORMATIONS S.P.C.M. SA (FR) 2013-01-10 WO disclosed
CN-102428157-A Novel formulation of water-soluble polymers and stabilizing additives for injection of a single compound useful as injection fluid for chemical enhanced oil recovery SPCM SA 2012-04-25 CN disclosed
WO-2011137135-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-11-03 WO disclosed
CN-102106903-A Application of dementholised peppermint oil to preparation of medicament for treating post-cholecystectomy blocked dynamic SICHUAN JISHENGTANG PHARMACEUTICALS CO LTD 2011-06-29 CN disclosed
US-7465747-B2 Fluorescent label compounds Matsumoto, Kazuko (JP) 2008-12-16 US disclosed
US-20050255465-A1 Novel fluorescent label compounds KAZUKO MATSUMOTO (JP) 2005-11-17 US disclosed
EP-1489418-A1 NOVEL FLUORESCENT LABEL COMPOUNDS Matsumoto, Kazuko (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050255465-A1 Novel fluorescent label compounds TRPC6, CHERP, FIBP FFAR3 3624/4885ALDH1A1 543/4885MEN1 1228/4885
US-20130029938-A1 Chemical Compounds CYP11B1, GOT2, CYP11B2 FFAR3 644/4885ALDH1A1 147/4885MEN1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.